[go: up one dir, main page]

EA201291463A1 - Составы для инфузии лантибиотиков типа b - Google Patents

Составы для инфузии лантибиотиков типа b

Info

Publication number
EA201291463A1
EA201291463A1 EA201291463A EA201291463A EA201291463A1 EA 201291463 A1 EA201291463 A1 EA 201291463A1 EA 201291463 A EA201291463 A EA 201291463A EA 201291463 A EA201291463 A EA 201291463A EA 201291463 A1 EA201291463 A1 EA 201291463A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lantibiotic
infantion
compositions
type
infusion
Prior art date
Application number
EA201291463A
Other languages
English (en)
Other versions
EA024344B1 (ru
Inventor
Энтони Николас Апплеярд
Сьёрд Николаас Вадман
Original Assignee
Новакта Биосистемс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новакта Биосистемс Лимитед filed Critical Новакта Биосистемс Лимитед
Publication of EA201291463A1 publication Critical patent/EA201291463A1/ru
Publication of EA024344B1 publication Critical patent/EA024344B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложен жидкий коллоидный фармацевтический состав лантибиотика типа В для инфузии или прямой инъекции, содержащий лантибиотик типа В или его соль, изотонический водный раствор, содержащий сахарный спирт, такой как глицерин и/или сахарид, и, возможно, буфер, при этом указанный готовый состав для инфузии или прямой инъекции не содержит видимых частиц.
EA201291463A 2010-08-11 2011-08-09 Составы для инфузии лантибиотиков типа b EA024344B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1013513.5A GB201013513D0 (en) 2010-08-11 2010-08-11 Formulations
PCT/GB2011/001191 WO2012020219A2 (en) 2010-08-11 2011-08-09 Formulations for infusion of type b lantibiotics

Publications (2)

Publication Number Publication Date
EA201291463A1 true EA201291463A1 (ru) 2013-07-30
EA024344B1 EA024344B1 (ru) 2016-09-30

Family

ID=42931511

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291463A EA024344B1 (ru) 2010-08-11 2011-08-09 Составы для инфузии лантибиотиков типа b

Country Status (9)

Country Link
US (1) US9192569B2 (ru)
EP (1) EP2603204A2 (ru)
JP (1) JP5865374B2 (ru)
CN (1) CN103108628B (ru)
CA (1) CA2807206A1 (ru)
EA (1) EA024344B1 (ru)
GB (1) GB201013513D0 (ru)
MX (1) MX2013001470A (ru)
WO (1) WO2012020219A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912035T3 (es) 2016-06-01 2022-05-24 Athira Pharma Inc Compuestos
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CN109620979B (zh) * 2018-12-29 2020-09-01 福建师范大学 低离子休克提高氨基糖苷类抗生素杀灭持留菌效率的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1013513A (en) 1963-03-25 1965-12-15 Watney Combe Reid & Co Ltd Improvements in and relating to hopping beer
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (ru) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
EP0700998B1 (en) 1994-09-12 2003-11-26 Aventis Pharma Deutschland GmbH Recombinant mersacidin and a method for production
ES2201189T3 (es) 1995-06-23 2004-03-16 Ambi Inc. Metodo para el control de bacterias gram positivas resistentes a antibioticos y tratamiento de la infeccion.
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
DE19745583A1 (de) 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
CN1321628C (zh) 2000-06-28 2007-06-20 史密斯克莱·比奇曼公司 湿磨方法
IL153688A0 (en) 2000-06-28 2003-07-06 Teva Pharma Carvedilol
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
WO2004033706A2 (en) 2002-10-10 2004-04-22 Molichem Medicines, Inc. Nucleic acids encoding duramycin
CA2502600A1 (en) * 2002-10-18 2004-05-06 Molichem Medicines, Inc. Methods of treating dry eye disease with lantibiotics
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
US7307057B2 (en) 2003-07-18 2007-12-11 Naicons S.C.A.R.L. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
CA2554537A1 (en) 2004-02-17 2005-09-01 Cancervax Corporation Method and composition for angiogenesis inhibition
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
EP1928900A1 (en) 2005-09-27 2008-06-11 Novacta Biosystems Limited Variants of the lantibiotic mersacidin and their use
GB0600928D0 (en) * 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
EP3954715A3 (en) 2006-10-27 2022-05-04 Capsugel Belgium NV Hydroxypropyl methyl cellulose hard capsules and process of manufacture
US20110150917A1 (en) 2007-06-12 2011-06-23 The University Of British Columbia Small Cationic Antimicrobial Peptides
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
CN102224164A (zh) 2008-11-24 2011-10-19 森蒂内拉制药公司 具有改进的抗菌活性的羊毛硫抗生素酰胺衍生物
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
RS53586B1 (en) 2009-01-14 2015-02-27 Novacta Biosystems Limited DERIVATION OF DECISION
NZ594675A (en) 2009-02-04 2013-11-29 Novacta Biosystems Ltd Actagardine derivatives
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
MX2012008819A (es) * 2010-02-02 2012-09-28 Novacta Biosystems Ltd Sales de lantibioticos.
JP2013531026A (ja) 2010-07-14 2013-08-01 ノヴァクタ バイオシステムズ リミティッド Ｂ型ランチビオティックを含む製剤

Also Published As

Publication number Publication date
CA2807206A1 (en) 2012-02-16
US20130137630A1 (en) 2013-05-30
CN103108628A (zh) 2013-05-15
JP2013533304A (ja) 2013-08-22
MX2013001470A (es) 2013-05-14
EA024344B1 (ru) 2016-09-30
WO2012020219A3 (en) 2012-04-05
JP5865374B2 (ja) 2016-02-17
WO2012020219A2 (en) 2012-02-16
CN103108628B (zh) 2015-08-05
US9192569B2 (en) 2015-11-24
EP2603204A2 (en) 2013-06-19
GB201013513D0 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
PH12014502778B1 (en) Antibody formulation
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201201659A1 (ru) Водная композиция, содержащая бромгексин
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
MY156188A (en) Long - acting formulations of insulins
UA122478C2 (uk) Водна фармацевтична композиція, яка містить моноклональне антитіло до pd-l1
PH12015500850A1 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CL2014001345A1 (es) Metodos de tratamiento usando un anticuerpo contra interferon gamma; usos composicion farmaceutica que contiene un anticuerpo contra interferon gamma.
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
WO2014199352A3 (en) Lipid-based platinum-n-heterocyclic carbene compounds and nanoparticles
AR098168A1 (es) Formulación estable de insulina glulisina
PE20150190A1 (es) Formulacion farmaceutica
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
EA201390467A1 (ru) Композиции антител и способы применения
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
PH12015500704A1 (en) Pharmaceutical composition comprising rebamipide
MX2014009660A (es) Formulacion de anticuerpo anti-selectina p.
EA201291463A1 (ru) Составы для инфузии лантибиотиков типа b
TR201100150A2 (tr) Suda çözünür dozaj formları
MX2014013083A (es) Composicion farmaceutica inyectable de dexketoprofeno y tramadol.
RU2011127039A (ru) Алкогольный напиток
ECSP13012846A (es) Nuevo compuesto con colageno hidrolizado

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU